Issue link: http://osercommunicationsgroup.uberflip.com/i/562595
C h a i n D r u g s t o r e D a i l y 8 5 Tu e s d a y, A u g u s t 2 5 , 2 0 1 5 ACHC both respect and recognition for being uniquely committed to the health- care industry. Much like the providers it serves, ACHC holds itself to the highest level of excellence in every aspect of its business. ACHC is the only accreditation organiza- tion with a Quality Management System certified to ISO 9001:2008 standards, a process that is key to operating efficient- ly and effectively while driving continu- ous improvement. With a consistent focus on excellence, ACHC offers pro- grams that help healthcare organizations achieve exceptional care. This commit- ment to quality is further demonstrated by ACHC maintaining CMS Deeming Authority for Home Health, Hospice, and DMEPOS. As a leading pharmacy accreditation organization, ACHC offers a full suite of services including infusion, specialty, long term care, DMEPOS, and PCAB compounding accreditation. Once a phar- macy achieves ACHC Accreditation in any of these programs, they are better positioned for competitive sustainability by demonstrating a higher level of excel- lence and the ability to deliver exception- al patient care. The accreditation process also results in additional benefits for pharmacies, including operational effi- ciencies, improved safety, risk avoidance and third-party payer recognition. ACHC has also illuminated the value for national community retail organizations to complete the accredita- tion process with minimal disruptions to daily business operations. Accordingly, a corporate accreditation program is avail- ACHC (Cont'd. from p. 1) able with a streamlined approach that provides additional support to help com- panies successfully achieve and maintain compliance on a national scale. A dedi- cated accreditation team at ACHC helps national community retail organizations navigate the accreditation process and offers the flexibility to quickly and easily add locations during periods of growth. At ACHC, experience has taught that continuing education is vital to achieving the highest quality of patient care. ACHC's Accreditation University is a comprehensive suite of resources designed to help providers achieve and maintain compliance with ACHC stan- dards and industry best practices. Providers may attend instructional accreditation workshops, reference the ACHC "Accreditation Guide to Success" workbooks or purchase additional educa- tional materials to improve their knowl- edge base and prepare for a successful survey. ACHC also customizes the edu- cational program to meet the unique needs of national organizations. With its sights fixed on future regu- latory and market conditions, ACHC helps its customers not only achieve and maintain compliance, but to also prepare for emerging issues. ACHC is highly focused on facilitating a higher level of performance across all business opera- tions for healthcare providers. As a CMS- deemed and ISO-certified accreditation organization, ACHC continues to embrace its mission to provide the best overall accreditation experience while helping providers to succeed by deliver- ing exceptional quality of care. Visit ACHC at booth #3510. shelf." Mentholatum is doing more than just introducing new products. "We're invest- ing time and resources in consumer research to ensure the items that we bring to market address consumer dissatisfac- tion with existing solutions," explained Jean Legros, Vice President of Sales and Marketing. Leading this turnaround was the 2014 launch of Softlips Cube. Combining form and function, this prod- uct provides five lip-perfecting benefits in one stylish balm. The formulation is designed to hydrate, smooth, replenish, protect and add shine. It's packaged in a unique, glass-like cube that not only commands attention, but is easy to find in a purse or make-up bag. Inside, the dome shaped balm makes it easy to apply. Product reviews consistently cite Softlips Cube as a step forward in performance and application. An example of Mentholatum's com- munication with consumers is the nation- al advertising campaign for Rohto Cooling Eye Drops that launched in March. Applying insights about the Millennial target, Mentholatum seized the opportunity to leverage the pop-cul- ture interest in zombies to dramatize a classic problem/solution message about Mentholatum (Cont'd. from p. 1) redness relief in its TV spot for the launch of Rohto Cool Max. This integrat- ed program – including digital and social media – has driven four consecutive weeks of record sales. Working with a panel of mothers in the development of Mentholatum Nighttime Vaporizing Rub paid off for the company. Those mothers provided feedback on existing chest rub formu- las, concerns facing families with sick kids and a desire for products that contain natural ingredients. Moms indicated that just as important as clearing congestion and treating coughs, was the desire for restorative sleep. As a result, Mentholatum's for- mulation uses natural active ingredi- ents to relieve cough and includes the aromatherapy benefit of soothing lavender. "For the last 13 weeks, Mentholatum has seen 40 percent growth for its oint- ment versus 12 percent growth for the chest rub category," shared DeMarco. To continue this innovation, Mentholatum will be converting to natural active ingre- dients in its other aromatic remedies for the upcoming cold season. Mentholatum also manufactures the newly launched Hada Labo Tokyo skin- care line, OXY Acne Medication, Red Cross oral care and other OTC and pri- vate label products. launch products rapidly, efficiently and effectively. Prasco's extensive industry experience, excellent customer support, interactive planning process and strong emphasis upon execution are vital com- ponents of this customizable infrastruc- ture. An additional element of Prasco's complete approach is long-term focus. Prasco is committed to creating solutions that have lasting worth for both the com- pany and its partners. Validating Prasco's complete approach is the fact that the company has 42 partnerships with brand compa- nies. These partnerships have returned Prasco (Cont'd. from p. 4) billions of dollars to brand companies through Authorized Generic product agreements. "I believe what sets Prasco apart from competitors is that our 'complete approach' is the way we approach every Authorized Generics opportuni- ty," said Jonathan Lapps, Prasco's Senior Vice President, Business Development. "Authorized Generics are our focus, and we build long-term partnerships where trust is reinforced through every interaction with that partner." For more information about Prasco Authorized Generics, visit booth #1108 or go to www.prasco.com. largely independently from Hospira, Mayne Pharma was sold to HalcyGen in 2009. In turn, HalcyGen changed its name to Mayne Pharma Group Limited a year later. Three years later, Mayne Pharma purchased Metrics Inc. Founded as a con- tract analytical laboratory in 1994 by a Burroughs Wellcome scientist and an ECU professor, Metrics was a privately- owned, specialty pharmaceutical compa- ny based in Greenville, North Carolina. The products manufactured by Metrics were sold in the United States via exclusive distribution partners or directly through Metrics' in-house wholesale distributor, Midlothian Laboratories. Mayne Pharma made a second U.S. acquisition within a year by buying pri- vately-held drug maker, Libertas Pharma Inc. on July 2, 2013. Libertas was a Mayne Pharma (Cont'd. from p. 4) generic pharmaceutical company head- quartered in Atlanta, Georgia, that dis- tributed and marketed a range of niche products. Midlothian Laboratories and Libertas Pharma were brought under the Mayne Pharma brand and became part of the newly formed Generic Product Division in August 2014. Most recently, Mayne Pharma announced the founda- tion of a third division, Specialty Brands Division, to manage its branded business after the acquisition of Doryx ® . With 170 years of dedication, inno- vation and growth, Mayne Pharma now boasts a significant product portfolio and pipeline, global distribution part- ners and two GMP compliant drug development and manufacturing facili- ties. Mayne Pharma is growing stronger and positioning itself for the next 100 years. Visit Mayne Pharma at booth #3316. high-quality products – many in new cat- egories such as specialty pharmacy as well as additional dosage forms. For the immediate future, we have focused on three areas of concentration: the development of high-value specialty products, including biosimilars, first to market generics, complex formulations and market shortage products; aligning our resources and expertise to efficiently produce the entire range of dosage forms such as hydrogel transdermal patches, inhalers and injectables; and enabling retail pharmacy to compete in all aspects of generic pharmaceuticals, further expanding their role in the total health- care spectrum. CDD: What should the industry expect from Amneal in 2016? CP: Candidly, the very same things you should expect from us today, and every day – that we will continue to dedicate ourselves to delivering quality generic drugs in the most efficient manner, with a constant focus on customer value and sat- isfaction. In the next 30 months we antic- ipate nearly 100 new product launches across various dosage forms, including many first-to-market and complex for- mulations, the result of our endless pas- sion to develop new, breakthrough prod- ucts across a growing variety of applica- Amneal (Cont'd. from p. 1) tions. We've created dedicated operating teams to develop, manufacture and mar- ket seven distinct dosage forms, which fosters strong commitment and execution in each category and encourages employ- ees to take ownership of their success. As Amneal grows into a world-class gener- ics player, smart international expansion is becoming more important. CDD: Is it a challenge to ensure Amneal's level of quality in the midst of such dramatic and sustained growth? CP: Expansion at the expense of the values upon which our company was founded would be self-defeating. Certainly, we will continue growing smartly, but we will take care to view every opportunity through the lens of quality and value for our customers. From the day we started our company in 2002, we have instilled in our people the fundamental belief that we serve a grander purpose than simply manufac- turing generics. We're here to help our customers and to improve their lives. As simple as it sounds, it is precisely this belief, in concert with our nimble, entre- preneurial spirit, that empowers our people to collaborate effectively in order to fulfill this mission. To learn more about Amneal, visit booth #106 or go to www.amneal.com.